drugset / Trial / NCT06532240

Methylene Blue for the Treatment of Septic Shock

NCT06532240

Phase 3 Completed 88 enrolled Northern Jiangsu People's Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of methylene blue among adult patients with septic shock.

Timeline

Start
2024-08-05
Primary completion
2025-10-24
Completion
2025-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylene Blue Diagnostic / imaging agent 0.25 mg/kg Intravenous